Evercore ISI on BioMarin (BMRN): 'INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy Biz'
Tweet Send to a Friend
Evercore ISI analyst Cory Kasimov reiterated an Outperform rating and $105.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
